{"id":962089,"date":"2026-05-13T08:04:15","date_gmt":"2026-05-13T12:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/"},"modified":"2026-05-13T08:04:15","modified_gmt":"2026-05-13T12:04:15","slug":"icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/","title":{"rendered":"ICON expands US early phase research capabilities with new clinic and outpatient centres"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>ICON expands US early phase research capabilities with new clinic and outpatient centres<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nNew, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof<\/p>\n<\/li>\n<li>\nTwo new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden<\/p>\n<\/li>\n<\/ul>\n<p>DUBLIN &amp; SAN ANTONIO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=54533237&amp;newsitemid=20260513228421&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=3505b0d9184adb70352e6af7f327af87\">ICON plc<\/a> (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON\u2019s capacity to conduct first-in-human, healthy participant, and patient cohort studies.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260513228421\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260513228421\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg\" alt=\"Welcoming visitors to ICON\u2019s new San Antonio Phase 1 clinic, purpose\u2011built to support early clinical development\" \/><\/p>\n<p style=\"font-size:85%\">Welcoming visitors to ICON\u2019s new San Antonio Phase 1 clinic, purpose\u2011built to support early clinical development<\/p>\n<\/div>\n<p>\nA key feature of the new San Antonio CRU is its fully integrated infrastructure. By co-locating the clinic, pharmacy, laboratory, and investigational product handling, ICON allows for faster dosing, immediate implementation of protocol changes, and accelerated delivery of data to sponsors. Onsite capabilities include a Good Manufacturing Practice \/ Good Clinical Practice (GMP\/GCP) compliant pharmacy and manufacturing space with International Organisation for Standardisation (ISO) cleanrooms, a clinical safety laboratory, and sample processing and shipping facilities.<\/p>\n<p>\nThis new facility has also been designed with participant comfort, safety, and experience as a priority. It features private and semi-private dormitories, recreation areas, dedicated clinical spaces, and advanced safety systems for continuous monitoring and rapid clinical response.<\/p>\n<p><i>&#8220;<\/i><i>We&#8217;ve designed the clinic to improve the experience of study participants, while scaling our capacity and maintaining our high-quality standards<\/i><i>,\u201d<\/i> said Dr. Ute Berger, ICON\u2019s Chief Medical Officer and President, Development Solutions. <i>\u201c<\/i><i>By fully integrating our clinical, laboratory, and pharmacy operations under one roof, we can largely eliminate logistical delays. This translates directly into faster dosing, real-time adaptability, and accelerated delivery of high-quality data for our sponsors. We are proud to invest in the San Antonio life sciences community and to contribute to its continued growth as a hub for innovation.\u201d<\/i><\/p>\n<p>\nIn addition to the San Antonio clinic, ICON\u2019s two new satellite outpatient facilities in Houston, Texas, and Lawrence, Kansas will further expand recruitment reach for its existing CRUs in the region. They will also provide greater flexibility for studies requiring extended Phase I follow-up, bringing care closer to participants and reducing travel burden.<\/p>\n<p>\nThe new San Antonio clinic joins ICON&#8217;s global network of dedicated Phase I clinical research units in Salt Lake City, Utah; Lenexa, Kansas; Groningen, Netherlands; and Budapest, Hungary, reflecting ongoing investment in providing market-leading services for early phase development and research.<\/p>\n<p><b>About ICON plc<\/b><\/p>\n<p>\nICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025. For further information about ICON, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=54533237&amp;newsitemid=20260513228421&amp;lan=en-US&amp;anchor=www.iconplc.com&amp;index=2&amp;md5=ca59b72fc0faf13c998b52e2895e21ed\">www.iconplc.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260513228421r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260513228421\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260513228421\/en\/<\/a><\/span><\/p>\n<p><b>Media contacts:<br \/>\n<\/b><br \/><b>ICON:<br \/>\n<\/b><br \/>Lisa Henry (GMT time zone)<br \/>\n<br \/>Weber Shandwick (PR adviser)<br \/>\n<br \/>+447785 458203<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lhenry@webershandwick.com\">lhenry@webershandwick.com<br \/>\n<\/a><br \/>ICON Press Office<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:iconnews@webershandwick.com\">iconnews@webershandwick.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas North America United States Ireland United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Consulting Biotechnology Professional Services Managed Care Health Pharmaceutical Medical Devices Research Hospitals Science Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/3\/Team_image.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Welcoming visitors to ICON\u2019s new San Antonio Phase 1 clinic, purpose\u2011built to support early clinical development<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800927\/3\/ICON_logo_high_res.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ICON expands US early phase research capabilities with new clinic and outpatient centres New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden DUBLIN &amp; SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON\u2019s capacity to conduct first-in-human, healthy participant, and patient cohort studies. This press release features &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ICON expands US early phase research capabilities with new clinic and outpatient centres&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962089","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ICON expands US early phase research capabilities with new clinic and outpatient centres New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden DUBLIN &amp; SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON\u2019s capacity to conduct first-in-human, healthy participant, and patient cohort studies. This press release features &hellip; Continue reading &quot;ICON expands US early phase research capabilities with new clinic and outpatient centres&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ICON expands US early phase research capabilities with new clinic and outpatient centres\",\"datePublished\":\"2026-05-13T12:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/\"},\"wordCount\":625,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513228421\\\/en\\\/2800929\\\/4\\\/Team_image.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/\",\"name\":\"ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513228421\\\/en\\\/2800929\\\/4\\\/Team_image.jpg\",\"datePublished\":\"2026-05-13T12:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513228421\\\/en\\\/2800929\\\/4\\\/Team_image.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513228421\\\/en\\\/2800929\\\/4\\\/Team_image.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ICON expands US early phase research capabilities with new clinic and outpatient centres\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/","og_locale":"en_US","og_type":"article","og_title":"ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk","og_description":"ICON expands US early phase research capabilities with new clinic and outpatient centres New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden DUBLIN &amp; SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON\u2019s capacity to conduct first-in-human, healthy participant, and patient cohort studies. This press release features &hellip; Continue reading \"ICON expands US early phase research capabilities with new clinic and outpatient centres\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:04:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ICON expands US early phase research capabilities with new clinic and outpatient centres","datePublished":"2026-05-13T12:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/"},"wordCount":625,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/","name":"ICON expands US early phase research capabilities with new clinic and outpatient centres - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg","datePublished":"2026-05-13T12:04:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260513228421\/en\/2800929\/4\/Team_image.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/icon-expands-us-early-phase-research-capabilities-with-new-clinic-and-outpatient-centres\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ICON expands US early phase research capabilities with new clinic and outpatient centres"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962089"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}